Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Investors put $400M into biotech licensing obesity drugs from China
May 16, 2024 · Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a disclosure posted on the Shanghai Stock Exchange Thursday.. The newly created company, currently referred to as “Hercules CM NewCo,” is backed by Bain Capital Life Sciences, RTW ...
Biotech M&A has plateaued. Track the deals that are happening …
Dec 30, 2024 · In 2024, the immune system edged out cancer as the top area of activity for bigger-ticket deals. BioPharma Dive tracked 14 immunology-focused buyouts, with upfront payments ranging from $90 million to nearly $5 billion.
Sanofi may have found a buyer for its consumer health business
Oct 11, 2024 · Opella sells well-known products like Allegra and Icy Hot, and, according to Sanofi, employs more than 11,000 people. The unit also operates in 100 countries, manages 13 manufacturing sites and operates four research centers.
Sanofi’s rare disease drug finds yet another home
Oct 4, 2024 · Enjaymo won U.S. approval in early 2022 after a winding journey. In 2014, the medicine was in development at San Francisco-based iPerian. But that year, Bristol Myers Squibb bought the company for its work in neurodegenerative diseases. iPerian’s programs targeting the immune system were spun out into a new biotechnology firm, True North Therapeutics.
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Approval in hand, Bristol Myers sets out to sell first-of-its-kind ...
Sep 26, 2024 · Carol Lim, a psychiatrist at Massachusetts General Hospital, noted in an interview this year how, after approval of the schizophrenia drug Caplyta in 2019, it was hard to get insurance coverage until after other treatments failed.. Cobenfy’s rollout will be handled by Bristol Myers Squibb, which recently acquired Karuna for $14 billion.Bristol Myers’ Chief Commercial Officer, Adam ...